| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA197: Dronedarone for the treatment of non-permanent atrial fibrillation |
|
Medicine details |
|
| Medicine name | dronedarone (Multaq®) |
| Formulation | 400 mg film-coated tablet |
| Reference number | 783 |
| Indication | Maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation. Due to its safety profile, dronedarone should only be prescribed after alternative treatment options have been considered. Dronedarone should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure |
| Company | Sanofi-Aventis Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/05/2009 |
| NICE guidance | TA197: Dronedarone for the treatment of non-permanent atrial fibrillation |